Archived News Releases


2016 | 2015 | 2014 | 2013 | 2012 | 2011
Keyword Search
 
DateTitle 
12/07/11ACADIA Pharmaceuticals to Present at the Oppenheimer 22nd Annual Healthcare Conference on December 14, 2011
SAN DIEGO--(BUSINESS WIRE)--Dec. 7, 2011-- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the Oppenheimer 22nd Annual Healthcare Conference on Wednesday, December 14, 2011, at 11:05 a.m. Eastern Time at The Waldorf=Astoria Hotel in New York City. ... 
Printer Friendly Version
11/09/11ACADIA Pharmaceuticals Reports Third Quarter 2011 Financial Results
SAN DIEGO, Nov 09, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results for the third quarter ended September 30, 2011. ACADIA reported a net loss of $5.1 million, or $0.10 per common share, for the third quarter of 2011 compared to a net loss of $4.2 million, or $0.11 ... 
Printer Friendly Version
11/07/11ACADIA Pharmaceuticals Advances AM-831 to Phase I Clinical Development in Collaboration with Meiji Seika Pharma
--FDA Accepts Investigational New Drug Application for AM-831-- SAN DIEGO, Nov 07, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that the U.S. Food and Drug Administration has completed its review of ACADIA's Investigational New Drug application to begin Phase I clinical studies with AM-831, ... 
Printer Friendly Version
11/02/11ACADIA Pharmaceuticals to Announce Third Quarter 2011 Financial Results on November 9, 2011
ACADIA to Host Conference Call and Webcast on Wednesday, November 9, 2011, at 5:00 p.m. Eastern Time SAN DIEGO, Nov 02, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will report its unaudited financial results for the third quarter ended September 30, 2011 on Wednesday, November 9, ... 
Printer Friendly Version
09/21/11ACADIA Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference on September 28, 2011
SAN DIEGO, Sep 21, 2011 (BUSINESS WIRE) --ACADIA Pharmaceuticals Inc. (Nasdaq:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the Sixth Annual JMP Securities Healthcare Conference on Wednesday, September 28, 2011, at 12:00 p.m. Eastern Time at The St. Regis Hotel in New York City. A live w... 
Printer Friendly Version
09/06/11ACADIA Pharmaceuticals to Present at the Rodman & Renshaw Annual Global Investment Conference on September 12, 2011
SAN DIEGO, Sep 06, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the Rodman & Renshaw Annual Global Investment Conference on Monday, September 12, 2011, at 4:30 p.m. Eastern Time at The Waldorf=Astoria Hotel in New York City. A live webcast of ACADIA's presentation ... 
Printer Friendly Version
08/10/11ACADIA Pharmaceuticals Reports Second Quarter 2011 Financial Results
SAN DIEGO, Aug 10, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today reported its unaudited financial results for the second quarter ended June 30, 2011. ACADIA reported a net loss of $6.6 million, or $0.12 per common share, for the second quarter of 2011 compared to a net loss of $4.3 million, or $0.11 per... 
Printer Friendly Version
08/03/11ACADIA Pharmaceuticals to Announce Second Quarter 2011 Financial Results on August 10, 2011
ACADIA to Host Conference Call and Webcast on Wednesday, August 10, 2011, at 5:00 p.m. Eastern Time SAN DIEGO, Aug 03, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will report its unaudited financial results for the second quarter ended June 30, 2011 on Wednesday, August 10, 2011, af... 
Printer Friendly Version
05/17/11ACADIA Pharmaceuticals Awarded Grant from National Institutes of Health for the Development of Novel ER-beta Agonists
SAN DIEGO, May 17, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has been awarded a grant from the National Institute of Neurological Disorders and Stroke (NINDS), a division of the National Institutes of Health (NIH), for the development of novel estrogen receptor beta (ER-beta) agonist... 
Printer Friendly Version
05/10/11ACADIA Pharmaceuticals Reports First Quarter 2011 Financial Results
SAN DIEGO, May 10, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced its unaudited financial results for the first quarter ended March 31, 2011. ACADIA reported a net loss of $5.8 million, or $0.12 per common share, for the first quarter of 2011 compared to a net loss of $5.5 million, or $0.14 per... 
Printer Friendly Version
05/04/11ACADIA Pharmaceuticals to Present at the Tenth Annual JMP Securities Research Conference on May 11, 2011
SAN DIEGO, May 04, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the Tenth Annual JMP Securities Research Conference on Wednesday, May 11, 2011, at 1:30 p.m. Pacific Time at The Ritz-Carlton Hotel in San Francisco. A live webcast of ACADIA's presentation will be accessi... 
Printer Friendly Version
05/03/11ACADIA Pharmaceuticals to Announce First Quarter 2011 Financial Results on May 10, 2011
ACADIA to Host Conference Call and Webcast on Tuesday, May 10, 2011, at 5:00 p.m. Eastern Time SAN DIEGO, May 03, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will report its unaudited financial results for the first quarter ended March 31, 2011 on Tuesday, May 10, 2011, after the ... 
Printer Friendly Version
04/01/11ACADIA Pharmaceuticals Announces Extension of Drug Discovery Collaboration with Allergan, Inc.
SAN DIEGO, Apr 01, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has extended its drug discovery and development collaboration with Allergan, Inc. (NYSE: AGN). The collaboration is focused on the discovery of innovative new therapeutics for glaucoma and other ophthalmic indications and w... 
Printer Friendly Version
03/29/11ACADIA Pharmaceuticals to Present at the Tenth Annual Needham Healthcare Conference on April 5, 2011
SAN DIEGO, Mar 29, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the Tenth Annual Needham Healthcare Conference on Tuesday, April 5, 2011, at 8:40 a.m. Eastern Time at The New York Palace Hotel in New York City. A live webcast of ACADIA's presentation will be accessible... 
Printer Friendly Version
03/10/11ACADIA Pharmaceuticals Reports Financial Results for the Fourth Quarter and Year Ended December 31, 2010
SAN DIEGO, Mar 10, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced its financial results for the fourth quarter and year ended December 31, 2010. ACADIA reported net income of $29.1 million, or $0.74 per common share, for the fourth quarter of 2010 compared to a net loss of $(8.7) million, or $(... 
Printer Friendly Version
03/03/11ACADIA Pharmaceuticals to Announce Fourth Quarter and Full Year 2010 Financial Results on March 10, 2011
ACADIA to Host Conference Call and Webcast on Thursday, March 10, 2011, at 5:00 p.m. Eastern Time SAN DIEGO, Mar 03, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will report its financial results for the fourth quarter and year ended December 31, 2010 on Thursday, March 10, 2011, aft... 
Printer Friendly Version
02/08/11ACADIA Pharmaceuticals to Present at the Thirteenth Annual BIO CEO & Investor Conference on February 15, 2011
SAN DIEGO, Feb 08, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (Nasdaq: ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it will present at the Thirteenth Annual BIO CEO & Investor Conference on Tuesday, February 15, 2011, at 8:30 a.m. Eastern Time at The Waldorf=Astoria Hotel in New York City. A live webcast of ACADIA's presentation will be a... 
Printer Friendly Version
01/10/11ACADIA Pharmaceuticals Announces $15 Million Private Placement
--Proceeds to Support Advancement of Pimavanserin Phase III Program-- SAN DIEGO, Jan 10, 2011 (BUSINESS WIRE) -- ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD), a biopharmaceutical company utilizing innovative technology to fuel drug discovery and clinical development of novel treatments for central nervous system disorders, today announced that it has entered into a securities purchase agreement for a private placement financing with a select group of institutional investors, including New Enterp... 
Printer Friendly Version